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Although the effects of aging on the neural correlates of schizophrenia have been 
researched for many years, no clear conclusion has been reached. While some studies have 
demonstrated progressive age-related gray matter reductions in schizophrenia, other studies 
have not found evidence of progression. Moreover, it remains unclear whether the influence 
of aging on global or regional cortical thickness differs between schizophrenia patients and 
healthy controls. This study aimed to confirm previous reports of reduced cortical thickness 
in schizophrenia, and to investigate the effects of age on global and regional cortical 
thickness. Eighty-three patients with schizophrenia (six first-episode patients and 77 
chronic patients; age range = 18-55 years) and 90 age-, gender- and education-matched 
healthy controls (age range = 19-56 years) underwent structural magnetic resonance 
imaging (MRI) using a 3-Tesla scanner. Surface-based analysis was applied to assess 
cortical thickness in the whole brain. The patient group exhibited both global and regional 
cortical thinning in regions including the prefrontal and temporal cortices. The correlation 
between age and cortical thickness showed a similar pattern in patients and controls, both 
globally and regionally. These results suggest that the reduction of cortical thickness in 
schizophrenia might not be progressive over the course of the illness, indicating that 
pathological processes occur in a relatively limited period of time around the onset of 
illness. 
 





Magnetic resonance imaging (MRI) studies have revealed anatomical alterations in 
multiple brain regions associated with schizophrenia. Global gray matter (GM) reductions 
in schizophrenia have been consistently reported (Gur et al., 1999; Lim et al., 1996; Sowell 
et al., 2000). In addition, regional GM reductions have been demonstrated by studies using 
region of interest (ROI) approaches (Shenton et al., 2001) and voxel-based morphometry 
techniques (Ashburner and Friston, 2000; Ellison-Wright et al., 2008; Honea at al., 2005), 
particularly in prefrontal and temporal regions. 
Although some of these alterations are already exhibited prior to illness onset, whether or 
not these anatomical brain alterations are progressive remains unclear (Borgwardt et al., 
2009; DeLisi 2008). Several longitudinal and cross-sectional studies have suggested 
progressive brain volume loss globally (Hulshoff Pol et al., 2002; Whitford et al., 2006) 
and regionally (Kasai et al., 2003; Mathalon et al., 2001; Whitford et al., 2006). Some 
studies, however, have reported negative findings regarding age-related global or regional 
progressive cortical loss (Bose et al., 2009; DeLisi and Hoff, 2005). Whitford et al. found 
progressive GM loss over the first few years of illness in first-episode schizophrenia, 
especially in the parietal and temporal cortices (Whitford et al., 2006), while Bose et al. 
reported that there was diminished GM volume loss with age in schizophrenia patients 
compared with controls, when correcting for differences in total brain volume (Bose et al., 
2009). 
Meanwhile, some recent studies have focused on reduced cortical thickness in 
schizophrenia (Goldman et al., 2009; Kuperberg et al., 2003; Nesvåg et al., 2008; Schultz et 
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al., 2010). Alterations of cortical thickness might reflect underlying pathological 
abnormalities such as reduced neuropil density, as revealed in postmortem studies of 
schizophrenia (Glantz et al., 2006). As such, directly examining changes in cortical 
thickness could help increase our understanding of the cause, mechanisms, and progression 
of the illness. However, only a few studies (Kuperberg et al., 2003; Nesvåg et al., 2008) 
have investigated the correlation between age and cortical thickness in patients with 
schizophrenia. These studies examined the effect of age on regional cortical thickness in 
schizophrenia, but an influence of aging on global cortical thickness has not been reported. 
To our knowledge, no study has simultaneously investigated global and regional cortical 
thickness in schizophrenia to determine whether it exhibits normal age-related changes, or 
represents a separate pathological process. Therefore, it remains unclear whether there is a 
progression of altered cortical thickness over the course of the illness. 
The present study aimed to elucidate whether age-related global and regional cortical 
thickness changes in patients with schizophrenia differ from those in healthy controls, and 
to examine whether these changes are progressive or not. 
It was predicted that global and regional cortical thickness would be reduced in 
schizophrenia. Surface-based analysis was applied to compare the pattern of the effects of 
aging on global and regional cortical thickness between patients with schizophrenia and 
healthy controls. In addition, we investigated whether or not the reduction of cortical 
thickness in schizophrenia would be progressive over the course of the illness. 
 




The schizophrenia group comprised 83 patients (six first-episode patients and 77 chronic 
patients; age range = 18-55 years) who were referred to the Department of Psychiatry at the 
Kyoto University Hospital. Each patient fulfilled the criteria for schizophrenia based on the 
Structural Clinical Interview for DSM-IV (SCID). The Positive and Negative Syndrome 
Scale (PANSS; Kay et al., 1987) was used to assess the severity of clinical symptoms. All 
patients were receiving antipsychotic medication (typical [n=9], atypical [n=56], typical 
and atypical [n=18]). Haloperidol equivalents were calculated according to the practice 
guidelines for the treatment of patients with schizophrenia (Inagaki and Inada, 2008; 
Lehman et al., 2004). 
The comparison group comprised 90 healthy individuals (age range = 19-56 years) who 
were matched to the schizophrenia group with respect to age, gender, and education level. 
They were also evaluated using the SCID and had no history of psychiatric disease, and 
they had no first-degree relatives with a history of psychotic episodes. The patients and 
controls were all physically healthy at the time of scanning. None had a history of 
neurological injury or disease, severe medical diseases, or substance abuse that could affect 
brain function. 
The estimated verbal and performance IQ (VIQ and PIQ) scores of each participant were 
obtained from vocabulary and block design subtests, respectively, in the Wechsler Adult 
Intelligence Scale-Revised, by transforming the scores corrected for age into T scores. 
This study was approved by the Committee on Medical Ethics of Kyoto University and 
was carried out in accordance with The Code of Ethics of the World Medical Association. 
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Written informed consent was obtained from each participant after a complete description 
of the study. 
 
2.2. MRI acquisition and pre-processing 
All participants underwent MRI scans on a 3-Tesla whole-body scanner equipped with 
an 8-channel phased-array head coil (Trio, Siemens, Erlangen, Germany). The scanning 
parameters of the T1-weighted three-dimensional magnetization-prepared rapid 
gradient-echo (3D-MPRAGE) sequences were as follows: TE = 4.38 ms; TR = 2000 ms; 
inversion time (TI) = 990 ms; FOV = 225 × 240 mm; matrix = 240 × 256; resolution = 
0.9375 × 0.9375 × 1.0 mm³; and 208 total axial sections without intersection gaps. 
For cortical thickness analysis in the whole brain, a surface-based approach was applied 
using FreeSurfer tools (version 4.5.0, http://surfer.nmr.harvard.edu; Dale et al., 1999; 
Fischl et al., 1999). The 3D-MPRAGE images were used to calculate thickness of the 
cerebral cortex throughout the cortical mantle. Briefly, the processing stream includes a 
Talairach transform of each subject’s native brain, removal of non-brain tissue, and 
segmentation of gray matter/white matter (GM/WM) tissue. The cortical surface of each 
hemisphere was inflated to an average spherical surface to locate the pial surface and the 
GM/WM boundary. The entire cortex of each subject was visually inspected, and any 
topological defects were corrected manually, blind to subject identity. Cortical thickness 
was computed as the shortest distance between the pial surface and the GM/WM boundary 
at each point across the cortical mantle. This method has been previously validated via 
histological as well as manual measurements in schizophrenia (Kuperberg et al., 2003). 
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Global mean cortical thickness for each subject was computed by averaging cortical 
thickness at each vertex, right and left hemispheres separately, and was used in the 
statistical analyses. The regional thickness value at each vertex for each subject was 
mapped to the surface of an average brain template (described at 
http://surfer.nmr.mgh.harvard.edu/fswiki/FsAverage). The cortical map of each subject was 
smoothed with a Gaussian kernel of 10-mm full-width at half-maximum for the entire 
cortex analyses. 
 
2.3. Statistical analyses 
2.3.1. Group comparison and regression analyses of global cortical thickness 
First, two independent sample t-tests were applied to examine group differences of 
demographic variables and global mean cortical thickness. Gender differences were 
examined using a chi-squared test. In the patient group, correlations between the mean 
cortical thickness and PANSS scores (positive, negative, and general psychopathology 
subscales), age of onset, and duration of illness (year), and medication were also examined. 
Data were analyzed using SPSS 15.0 (SPSS Inc., Chicago, IL, USA). The statistical 
significance level was set at p<0.05. 
Second, using SPSS, a multiple regression model was applied to detect the effects of age, 
and the age-diagnosis interaction on global mean cortical thickness. The global mean 
cortical thickness was analyzed separately for each hemisphere. Thus, the dependent 
variables were mean cortical thickness of the right and left hemispheres, while the 
independent variables were age, diagnosis (dummy parameterized, control = 1, 
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schizophrenia = 0), and their interactions. 
 
2.3.2. Group comparison of regional cortical thickness 
The general linear model (GLM) was implemented at each vertex in the whole brain to 
identify brain regions in which schizophrenia patients showed significant differences in 
cortical thickness relative to controls, using FreeSurfer’s mri_glmfit (described at 
http://surfer.nmr.mgh.harvard.edu/fswiki/mri_glmfit). In the patient group, the cortical 
regions showing correlations with PANSS scores (positive, negative, and general 
psychopathology subscales), age of onset, duration of illness, and medication were also 
examined. The effects of age and gender were regressed out in these models. All the 
analyses were performed for the right and left hemispheres separately. The threshold was 
set at p<0.05 (False Discovery Rate; [FDR]; Genovese et al., 2002) to resolve the problem 
of multiple comparisons. 
2.3.3. Correlational analyses between regional cortical thickness and age 
First, vertex-wise GLM analyses were performed in the control and patient groups 
independently to explore the brain regions that showed significant correlations between 
cortical thickness and age both in controls and schizophrenia patients, using mri_glmfit. 
Second, the interaction between diagnosis and age was examined to examine the difference 
in age regression slopes between both groups, modeling another design that included both 
groups. All of these analyses were performed on the right and left hemispheres separately. 
The same threshold of p<0.05 (FDR) was applied. 
Third, to investigate the regional aging effect in more detail, age regression slopes of 
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controls and patients were compared within regions exhibiting significant cortical thinning 
in the schizophrenia group. Contiguous regions exhibiting significant cortical thinning in 
the group comparison were selected as ROIs. ROIs were automatically mapped onto each 
subject, from which the mean thickness of each ROI was calculated. Two-tailed t-tests were 
applied to compare z-transformed correlation coefficients of age and regional mean cortical 
thickness within each ROI between the both groups. In addition, because 
regionally-specific effects of medication have been previously reported (Navari and Dazzan, 
2009; Smieskova et al., 2009), possible correlations between cortical thickness and 
medication were further examined within each ROI. Data were analyzed using SPSS 15.0. 
Statistical significance was defined as p<0.05.  
 
2.3.4 Effect of medication type 
To test the possible effects of medication type, we divided the patients into three 
subgroups (typical = patients taking typical antipsychotics; atypical = patients taking 
atypical antipsychotics; and combined = patients taking combined therapy with both typical 
and atypical antipsychotics). 
To examine effect of medication type on global cortical thickness, an analysis of 
covariance (ANCOVA) was applied within each hemisphere. In addition to age and gender, 
the haloperidol equivalent dosage was included as a nuisance covariate in the model, to 
examine the effect of medication type separately from dose effect. 
To examine the effect of medication type on regional cortical thickness, we performed 
between-subgroup comparisons using vertex-wise GLM analyses throughout the whole brain. 
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In addition, an ANCOVA was applied to examine the effect of medication type in each ROI 
that showed significant cortical thinning in patients compared with healthy controls. Age, 




3.1. Demographic data 
Demographic and clinical data are shown in Table 1. The estimated VIQ and PIQ were 
significantly lower in the patient group (patients’ data were available for 77 subjects) than 
the control group. There was no significant difference in education level or gender between 
both groups. 
 
3.2. Group comparison and regression analyses of global mean cortical thickness 
For the global mean cortical thickness, the patient group showed a significant reduction 
in both hemispheres (Table 2a). 
In the patient group, significant correlations were found between cortical thickness and 
the age of onset, and between cortical thickness and duration of illness. That is, a higher 
age of onset and longer duration of illness were associated with lower cortical thickness. 
However, in both hemispheres cortical thickness was not correlated with scores on the 
positive, negative, and general psychopathology subscales of the PANSS, or with 
medication (Table 2b). 
The regression analyses revealed significant main effects of age (p<0.001 for both 
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hemispheres) and diagnosis (p<0.001 for both hemispheres), but no significant interaction 
between them. 
A scatter plot of mean cortical thickness against age is shown in Fig. 1. The regression 
line of patients with schizophrenia was almost parallel to that of normal subjects for both 
hemispheres. 
To examine patients in the chronic stage only, a supplementary investigation of the 
effects of age, and the age-diagnosis interaction on global mean cortical thickness was 
performed by eliminating the six first-episode patients from our sample. We found that the 
results did not change significantly when chronic stage patients were examined alone. 
Because highly significant correlations were found between cortical thickness and 
duration of illness in the patient group, further analyses were performed to examine the 
effects of illness on cortical thickness in more detail. Since duration of illness was highly 
correlated with age (r=0.713, p<0.001), step-wise regression analyses were performed, with 
global cortical thickness of the right and left hemisphere as dependent variables, and 
duration of illness and age as independent variables. In this model, only age remained 
significant (p<0.001 for both hemispheres). 
 
3.3. Group comparison of regional cortical thickness 
The patient group exhibited reduced cortical thickness compared with the control group 
in several regions, including frontal, temporal, parietal, and limbic structures in both 
hemispheres (Fig. 2). Highly significant differences were found in bilateral rostral middle 
frontal areas, bilateral superior frontal areas, the right insula, right isthmus, right precuneus, 
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right superior temporal, and right middle temporal area. The results revealed no regions in 
which the patient group exhibited a greater cortical thickness than the control group. In the 
patient group, regional cortical thickness did not correlate with scores on the positive, 
negative, or general psychopathology subscales of PANSS, age of onset, duration of illness, 
and medication. 
 
3.4. Correlational analyses between regional cortical thickness and age 
Cortical thickness in widespread regions including the frontal, temporal, parietal and 
occipital areas was found to be negatively correlated with age in the control group, and a 
similar pattern was detected in the patient group (Fig. 3a, 3b). Highly significant 
correlations were shown in the frontal and temporal regions in both groups. There was no 
effect of an interaction between diagnosis and age on thickness in the vertex-wise GLM 
analysis. 
Eight regions of significant cortical thinning in schizophrenia found in the group analysis 
were selected as ROIs (Fig. 2, Table 3). Results from the comparison of correlation 
coefficients of mean thickness and age in each ROI are shown as scatter plots in Fig. 4. The 
age regression slopes within all these ROIs did not significantly differ between groups 
(p value range = 0.215 – 0.960). 
Significant correlations were found between cortical thickness and medication in the 
ROIs in the right superior frontal (SF; r=-0.304, p=0.005) and left SF (r=-0.234, p=0.033) 




3.5 Effect of medication type 
  No significant differences in cortical thickness were found among medication type 
subgroups in an ANCOVA examining global cortical thickness, in vertex-wise GLM 
analyses, or in an ANCOVA examining regional cortical thickness within each ROI. 
 
4. Discussion 
The effect of aging on regional cortical thickness in schizophrenia has been examined in 
a small number of previous studies (Kuperberg et al., 2003; Nesvåg et al., 2008), but the 
effect of aging on global cortical thickness in schizophrenia is currently not clear. Moreover, 
whether the alteration in cortical thickness associated with the disorder is progressive or not 
remains an open question. 
To our knowledge, this is the first study to examine the effects of aging on both global 
and regional cortical thickness simultaneously in detail in schizophrenia, and to investigate 
whether the cortical thickness reduction associated with the disease is progressive or not. 
The group comparison of global cortical thickness revealed reduced global cortical 
thickness in patients with schizophrenia. Our results indicated a global GM volume 
reduction in schizophrenia, similar to that shown previously (Gur et al., 1999; Lim et al., 
1996; Sowell et al., 2000). Our examination revealed that a variety of specific regions were 
affected in terms of thickness in patients with schizophrenia, including the prefrontal and 
temporal cortices. This finding is consistent with previous volumetric and cortical thickness 
studies (Ellison-Wright et al., 2008; Kuperberg et al., 2003, Nesvåg et al., 2008), and 
suggests that GM volume reduction might reflect pathological abnormalities that cause 
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reduced cortical thickness in schizophrenia. 
The correlation between age and cortical thickness was a major finding of this study. 
The effect of age on cortical thickness was found to be similar in patients compared with 
controls, both globally and regionally. Moreover, the results of our step-wise analyses 
indicated that age contributed to the variance in global cortical thickness more than the 
duration of illness in schizophrenia patients. 
Although our results appear inconsistent with previous volumetric studies focusing on 
progressive GM loss (Hulshoff Pol et al., 2002; Mathalon et al., 2001), more recent studies 
have suggested that substantial progressive global and regional alterations are not exhibited 
over the entire course of the illness, but are most prominent in a relatively early stage of the 
illness (Bose et al., 2009; Sun et al., 2009; Takahashi et al., 2010; Whitford et al., 2006). 
One possible explanation for this inconsistency is that educational levels in the studies by 
Hulshoff Pol et al. (2002) and Mathalon et al. (2001) were lower in the patient group than 
in controls. Differences in education level may affect cortical thickness, directly or latently. 
In addition, it is possible that the absence of an interaction between diagnosis and age was 
due to the inclusion of only six first-episode patients in this study. A number of recent 
neuroimaging studies have provided evidence for brain alterations in individuals at a high 
risk of psychosis, and during the early phases of schizophrenia (Haller et al., 2009; Jung et 
al., 2009; Smieskova et al., 2010; Wood et al., 2008). Although one previous study 
suggested that cortical thickness asymmetry might be more sensitive for the early detection 
of illness (Haller et al., 2009), most of these studies have reported reduced cortical 
thickness and GM volume in the prefrontal, anterior cingulate, and temporal regions. The 
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pattern of cortical thinning shown by the schizophrenia group in our study was largely 
similar to that in previous studies, but the thinning was more widespread than that found in 
individuals at a high risk of psychosis (Jung et al., 2009). Taken together with previous 
studies, our findings indicate that pathological alterations in cortical thickness might occur 
at a relatively early phase of the illness, and that changes might be within the normal range 
in later phases. 
Previous studies reported a possible correlation between symptom severity and altered 
GM volume (Hulshoff Pol and Kahn 2008; Mathalon et al., 2001). The lack of a correlation 
with symptom severity in the present results may have been due to the inclusion of patients 
with mild symptoms. 
Among the eight ROIs, weak but significant negative correlations between dosage and 
cortical thickness were found within the right and left SF cortices. Although previous 
studies reported inconsistent findings regarding the effect of medication on cortical 
thickness or volume, this negative correlation is consistent with other studies reporting 
associations between antipsychotic medication and regional gray matter volume reductions 
within the frontal lobe (Navari and Dazzan, 2009; Smieskova et al., 2009). Because of the 
cross-sectional, correlational design of the current study, it is difficult to determine whether 
antipsychotic medication caused cortical thinning, or whether patients with lower cortical 
thickness in these regions require a larger amount of medication. As such, a longitudinal 
study will be necessary to investigate the effects of medication on cortical thickness. 
We did not find any differences in cortical thickness among medication type subgroups 
(typical, atypical, or combined), globally or regionally, suggesting that the effects of 
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antipsychotics on cortical thickness do not differ among these medication types. However, 
larger studies will be needed to further investigate the effects of antipsychotic types in 
future, because the sample sizes of the typical group (n=9) and combined group (n=18) in 
the current study are smaller than is desirable for interpreting such differences. 
Several limitations involved in the present study should be considered. First, since the 
study design was cross-sectional rather than longitudinal, the effects of aging should be 
interpreted with caution. Although our results provide some useful suggestions, a 
cross-sectional design does not allow decisive conclusions to be drawn regarding 
disease-related cortical thinning and the progression of cortical thinning over the course of 
the illness. Second, because different types of antipsychotic drugs might have different 
effects on cortical structure (Navari and Dazzan, 2009; Salimi et al., 2009), the possible 
effects of medication cannot be entirely excluded in this study. Third, all of the patients 
included in our study exhibited mild and stable symptoms, which might be associated with 
relatively small changes in cortical thickness. Finally, in this study we used FreeSurfer 
tools to perform analyses on cortical thickness. Because the use of different image analysis 
techniques (Fusar-Poli et al., 2010) might have caused heterogeneity between previous 
studies of cortical thickness in schizophrenia patients, the findings of this study should be 
confirmed using other image analysis techniques. Future research will be required to test 
the generalizability of these results. 
In conclusion, the present study revealed that schizophrenia was associated with reduced 
global and regional cortical thickness, and a similar correlation between age and thickness 
was found in patients with schizophrenia and healthy controls. These results suggest that a 
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reduction of cortical thickness in schizophrenia may occur within a relatively early period 
of the illness, and might reflect pathological processes in a relatively limited period around 
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Statistical maps corrected for age and gender showing reduced cortical thickness in patients 
with schizophrenia relative to controls. Maps are shown for right and left hemispheres in 
lateral and medial views respectively, and significant regions are shown in red. P<0.05 
(False Discovery Rate [FDR]) 
Yellow arrows and fonts indicate regions of interest (ROIs) in the ROI analyses. 
Abbreviations, r = right, l = left, RMF = rostral middle frontal, SF = superior frontal, ST = 
superior temporal, MT = middle temporal, Isth = isthmus, Precun = precuneus. Anatomical 




Statistical maps showing the regions of cortical thickness negatively correlated with age in 
(a) the control group and (b) the patient group. Maps are shown for right and left 
hemispheres in lateral and medial views respectively, and significant regions are shown in 




Scatter plots and regression slopes of regional mean cortical thickness with age in each 
region of interest (ROI). 
Abbreviations, r = right, l = left, RMF = rostral middle frontal, SF = superior frontal, ST = 
superior temporal, MT = middle temporal, Isth = isthmus, Precun = precuneus. Anatomical 
terms are used according to the Desikan template (Desikan et al., 2006).
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 Mean S.D.  Mean S.D.  t p 
Age (years) 34.3 10.9  35.7 10.1  -0.91 N.S. b 
Gender (male/female) 39/51   44/39    N.S. c 
Handedness (right/left) 87/3   79/4     
Education (years) 14.0 2.3  13.4 2.2  1.59 N.S. b 
Estimated VIQ (Vocabulary) a 112.2 15.2  98.8 17.8  5.18 p<0.001 
Estimated PIQ (block design) a 116.6 15.0  103.3 17.3  5.32 p<0.001 
PANSS positive    14.1 5.5    
PANSS negative    16.7 6.1    
PANSS general    31.6 9.2    
PANSS total    62.4 17.3    
Age of onset    24.8 7.4    
Duration of illness (years)    11.0 9.2    
Medication (mg/day, haloperidol 
equivalent) 
   10.6 6.8    
Abbreviations, VIQ = verbal IQ; PIQ = performance IQ; PANSS = Positive and Negative 
Syndrome Scale (Kay et al., 1987). 
a Patients’ data were available for 77 subjects  
b Two-tailed t tests, α = 0.05 
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c Two-tailed chi-squared test, α = 0.05 
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  Control group (n=90)  Patient group (n=83)  Statistics 
  Mean S.D.  Mean S.D.  t p 
Right hemisphere 2.55 0.09  2.48 0.11  4.28 p<0.001 
Left hemisphere 2.54 0.09  2.49 0.10  3.92 p<0.001 
 
Table 2b Correlational analyses of mean cortical thickness in the patient group 
 
Cortical thickness  
(Right hemisphere) 
Cortical thickness  
(Left hemisphere) 
 Pearson's r p  Pearson's r p 
PANSS positive -0.080 N.S.  -0.154 N.S. 
PANSS negative 0.095 N.S.  0.100 N.S. 
PANSS general 0.028 N.S.  -0.011 N.S. 
Age of onset -0.260 p=0.018  -0.224 p=0.042 
Duration of illness (year) -0.372 p=0.001  -0.348 p=0.001 
Medication (mg/day, 
haloperidol equivalent) 
-0.166 N.S.  -0.186 N.S. 
 Abbreviations, PANSS = Positive and Negative Syndrome Scale (Kay et al., 1987). 
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Table 3 Statistics within each region of interest (ROI), selected from significant cortical 
thinning regions in schizophrenia in the group analysis 














 Mean S.D.  Mean S.D.  t p 
Right rostral middle frontal 2.51 0.17  2.36 0.16  5.76 p<0.001 
Right superior frontal 3.05 0.17  2.87 0.19  6.42 p<0.001 
Right insula 2.77 0.15  2.62 0.14  6.59 p<0.001 
Right isthmus/precuneus 2.75 0.16  2.58 0.16  6.65 p<0.001 
Right superior/middle temporal 2.85 0.22  2.68 0.23  5.06 p<0.001 
Left rostral middle frontal 2.43 0.10  2.37 0.12  3.76 p<0.001 
Left superior frontal 3.02 0.17  2.87 0.19  5.90 p<0.001 
Left superior/rostral middle frontal 2.76 0.17  2.62 0.16  5.36 p<0.001 
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